Hepple intends to transfer Kymab's stake, which was acquired by Sanofi

On January 11th Heppry announced that Its wholly-owned subsidiary, Hong Kong Heppry, held a fully diluted 8.66 per cent stake in Kymab.
FP BV, a wholly owned subsidiary of Sanofi, signed an equity transfer agreement with all Kymab shareholders, including Hong Kong-based Hepple, to take a full stake in Kymab.
's full stake in Kymab was valued at $1.1 billion in the down payment, followed by a milestone bid of no more than $350 million.
Sanofi expects the deal to close in the second quarter of 2021.
has invested approximately $4,056.62 million in Kymab's current equity.
the deal, the deal includes an initial offer of about $117 million and a subsequent milestone of no more than $30.3 million.
, Kymab is a Cambridge, UK-based clinical stage biopharmaceutical company focused on discovering and developing all-human monoclonal antibody drugs using its proprietary Antibody Platform (IntelliSelect®®, which covers the entire human antibody system.
has a wide range of therapeutic antibody project pipelines, with significant growth potential for immunotherapy candidates KY1005, KY1044, etc.
2017, Hong Kong-based Heppry acquired Kymab's 8,487,385 C-Series Preferred Shares for $36.5 million.
2019, Hong Kong-based Heppry bought its convertible preferred stock for $3.5 million.
August 2020, Hong Kong-based Heppell will subscribe for 324,149 Preferred B shares and 109,105 Series C Preferred Shares as a rights issued by Kymab to shareholders for ￡431,000.
said the counterparty, Sanofi FP BV, was a subsidiary of Sanofi with Sanofi Chimie, the company's main heparin raw material customer.
the deal, Sanofi FP BV will become Kymab's sole shareholder and Heppey will no longer hold an interest in Kymab.